ATE119198T1 - Verfahren zur herstellung von proteinen mittels rekombinanter dna. - Google Patents

Verfahren zur herstellung von proteinen mittels rekombinanter dna.

Info

Publication number
ATE119198T1
ATE119198T1 AT89303767T AT89303767T ATE119198T1 AT E119198 T1 ATE119198 T1 AT E119198T1 AT 89303767 T AT89303767 T AT 89303767T AT 89303767 T AT89303767 T AT 89303767T AT E119198 T1 ATE119198 T1 AT E119198T1
Authority
AT
Austria
Prior art keywords
recombinant dna
producing proteins
host cell
synthesised
dna sequence
Prior art date
Application number
AT89303767T
Other languages
English (en)
Inventor
Raymond John Owens
Gregory Paul Winter
Lutz Riechmann
Geoffrey Thomas Yarranton
Mark William Bodmer
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE119198(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888809050A external-priority patent/GB8809050D0/en
Priority claimed from GB888811342A external-priority patent/GB8811342D0/en
Priority claimed from GB888820284A external-priority patent/GB8820284D0/en
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ATE119198T1 publication Critical patent/ATE119198T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89303767T 1988-04-16 1989-04-17 Verfahren zur herstellung von proteinen mittels rekombinanter dna. ATE119198T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888809050A GB8809050D0 (en) 1988-04-16 1988-04-16 Expression of antibody heavy & light chain variable domains as an fv-fragment
GB888811342A GB8811342D0 (en) 1988-05-13 1988-05-13 Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
GB888820284A GB8820284D0 (en) 1988-08-26 1988-08-26 Method for producing recombinant dna proteins

Publications (1)

Publication Number Publication Date
ATE119198T1 true ATE119198T1 (de) 1995-03-15

Family

ID=27263864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89303767T ATE119198T1 (de) 1988-04-16 1989-04-17 Verfahren zur herstellung von proteinen mittels rekombinanter dna.

Country Status (9)

Country Link
EP (1) EP0338745B1 (de)
JP (2) JP3105898B2 (de)
AT (1) ATE119198T1 (de)
AU (1) AU627183B2 (de)
CA (1) CA1341411C (de)
DE (1) DE68921364T2 (de)
ES (1) ES2070172T3 (de)
GR (1) GR3015248T3 (de)
WO (1) WO1989009825A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
EP0861893A3 (de) * 1991-09-19 1999-11-10 Genentech, Inc. Hohe expression von immunglobulinen
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
AU706056B2 (en) * 1995-10-13 1999-06-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxin containing a disulfide-stabilized antibody fragment
AU7288196A (en) * 1995-10-20 1997-05-15 Ciba-Geigy Ag Process for the preparation of a single chain fv antibody fragment
DE69724428T3 (de) 1996-06-07 2009-07-23 Poniard Pharmaceuticals, Inc., Seattle Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
JP2000164361A (ja) 1998-11-25 2000-06-16 Tdk Corp 有機ｅｌ素子
EE200100603A (et) 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
CA2419148C (en) 2000-05-16 2011-07-12 Thomas Jefferson University Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
DK2508596T3 (en) 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
ES2534926T3 (es) 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
EP1735348B1 (de) 2004-03-19 2012-06-20 Imclone LLC Humaner antikörper gegen den rezeptor des epidermalen wachstumsfaktors
DE602005024850D1 (de) 2004-09-24 2010-12-30 Beth Israel Hospital Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
CN101102791B (zh) 2004-11-18 2011-12-14 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
EP1812064A4 (de) 2004-11-19 2009-07-08 Cornell Res Foundation Inc Verwendung vaskulärer endothelwachstumsfaktor-rezeptor-1+-zellen bei der behandlung und überwachung von krebs und beim screening bei chemotherapie
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
CN101253199B (zh) 2005-08-30 2019-06-14 迈阿密大学 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
MY157757A (en) 2006-07-18 2016-07-15 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
NO2195023T3 (de) 2007-08-29 2018-08-04
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
MX2010010021A (es) 2008-03-12 2011-02-15 Imclone Llc Anticuepos anti-tyrp1.
AU2008361352B2 (en) 2008-09-07 2013-05-09 Glyconex Inc. Anti-extended Type I glycosphingolipid antibody, derivatives thereof and use
US9163086B2 (en) 2009-08-18 2015-10-20 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
EP2533810B1 (de) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20-antikörper und ihre verwendung
CN102844050B (zh) 2010-02-19 2019-02-05 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
EP3235508B1 (de) 2011-03-16 2020-12-30 Sanofi Zubereitungen enthaltend ein antikörperähnliches protein mit dualer v-region
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN113891729A (zh) 2019-05-24 2022-01-04 赛诺菲 治疗系统性硬化症的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382317D1 (de) * 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3785186T2 (de) * 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.

Also Published As

Publication number Publication date
GR3015248T3 (en) 1995-06-30
JP3105898B2 (ja) 2000-11-06
AU627183B2 (en) 1992-08-20
DE68921364T2 (de) 1995-06-29
WO1989009825A1 (en) 1989-10-19
JPH03500005A (ja) 1991-01-10
DE68921364D1 (de) 1995-04-06
EP0338745B1 (de) 1995-03-01
AU3536489A (en) 1989-11-03
CA1341411C (en) 2002-12-17
ES2070172T3 (es) 1995-06-01
JPH11225758A (ja) 1999-08-24
EP0338745A1 (de) 1989-10-25

Similar Documents

Publication Publication Date Title
ATE119198T1 (de) Verfahren zur herstellung von proteinen mittels rekombinanter dna.
ATE91716T1 (de) Verfahren zur herstellung vielkettige polypeptide oder proteine.
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DK368588D0 (da) Bindingsmolekyler med en enkelt plypeptidkaede
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
Remington et al. Biosynthesis of a disulphide-bonded short-chain collagen by calf growth-plate cartilage
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
FI102383B1 (fi) Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
ATE72458T1 (de) Zugeordnete ribosomen und ihre verwendung zur herstellung von proteinen aus zellkulturen.
HUP9801330A2 (hu) Új PKA-kötő fehérjék és alkalmazásuk
ATE162853T1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
EP0688224A4 (de) Ein mutiertes protein und verfahren und materialien zu seiner herstellung und verwendung
DE60040789D1 (de) Verfahren zur aufreinigung heterologer proteine
DE69634297D1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
DE69721629D1 (de) An Nukleinsäure gebundenes Polypeptid, Verfahren zur Herstellung eines an Nukleinsäure gebundenen Polypeptides und Immunoassay, in dem dieses Polypeptid Verwendung findet
DK1241185T3 (da) Nucleinsyrer, der er opformeret i humane tumorer, samt beslægtede materialer og fremgangsmåder
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder